别名 A2MR、Alpha-2-macroglobulin receptor、APOER + [17] |
简介 Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells (PubMed:11907044, PubMed:12713657). Required for early embryonic development (By similarity). Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. Acts as an LRPAP1 alpha-2-macroglobulin receptor (PubMed:26142438, PubMed:1702392). Acts as TAU/MAPT receptor and controls the endocytosis of TAU/MAPT as well as its subsequent spread (PubMed:32296178). May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission (PubMed:12888553).
(Microbial infection) Functions as a receptor for Pseudomonas aeruginosa exotoxin A. |
作用机制 LRP1 modulators [+3] |
在研机构 |
原研机构 |
在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 LRP1激动剂 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 LRP1 antagonists |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-12-01 |
申办/合作机构 |
开始日期2022-09-15 |
申办/合作机构- |
开始日期2022-05-24 |
申办/合作机构 香港欣诺康医药科技有限公司 [+1] |